Vaccine stocks drop after feds' reassurance on swine flu vax supplies; Celldex starts early-stage study on tumor vaccine;

Swine Flu

> HHS says that it will have all the vaccine it needs this fall, an unexpected development that triggered a quick correction at a slate of biotech companies which had seen their shares boosted by the prospect of a vaccine shortage that could force health officials to jump-start an approval. Story

> Cel-Sci and Novavax, which are both working on swine flu-related products, are planning to raise a combined $30 million in new financing. Report

> The Indian government issued a high-profile appeal to big vaccine manufacturers to conduct trials of their swine flu vaccine in the subcontinent. The Business Standard says that "only" two responded. But they were both big. Novartis and GlaxoSmithKline have both sought regulatory approval of a vaccine trial. Story

> CNN took a tour of Sinovac Biotech's swine flu production facility in China. Sinovac was the first developer to gain an approval for a swine flu vaccine and begin production. Report

> The Japanese government plans to buy 50 million doses of swine flu vaccine from GlaxoSmithKline and Novartis. That's on top of the 18 million doses that can be produced inside the country. Story

Vaccine Research

> Celldex Therapeutics has initiated dosing in a Phase I/II study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1. Release

> Sanaria has won a two-year, $1.99 million grant from the National Institute of Allergy and Infectious Diseases. Continued funding for a third year will bring the total to nearly $3 million. Story

Vaccine Market

> Canadian officials are considering Merck's request to extend its HPV vaccine to boys and young men. Report

> Veterinarians are recommending a new vaccine to prevent canine influenza virus in dogs. Story